Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

0.90USD
4:00pm EDT
Change (% chg)

$-0.03 (-3.08%)
Prev Close
$0.93
Open
$0.92
Day's High
$0.94
Day's Low
$0.90
Volume
152,666
Avg. Vol
231,486
52-wk High
$6.77
52-wk Low
$0.79

Latest Key Developments (Source: Significant Developments)

Genocea Reports Qtrly Loss Per Share $0.21
Thursday, 10 May 2018 07:59am EDT 

May 10 (Reuters) - Genocea Biosciences Inc ::GENOCEA REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS.GENOCEA BIOSCIENCES INC - QTRLY LOSS PER SHARE $0.21.GENOCEA BIOSCIENCES INC - SEES CASH AND CASH EQUIVALENTS AS SUFFICIENT TO SUPPORT OPERATING EXPENSES, CAPEX REQUIREMENTS INTO Q4 2019.  Full Article

Genocea Biosciences Says Jonathan Poole Delivered Resignation As CFO
Friday, 9 Mar 2018 04:51pm EST 

March 9 (Reuters) - Genocea Biosciences Inc ::GENOCEA BIOSCIENCES - ‍ON MARCH 6, JONATHAN POOLE DELIVERED RESIGNATION AS CFO EFFECTIVE MARCH 23, 2018​.GENOCEA BIOSCIENCES SAYS PENDING CONCLUSION OF CFO SEARCH, CEO WILLIAM CLARK TO ASSUME DUTIES OF PRINCIPAL FINANCIAL OFFICER - SEC FILING.  Full Article

Genocea Qtrly Loss Per Share $0.37
Thursday, 15 Feb 2018 08:00am EST 

Feb 15 (Reuters) - Genocea Biosciences Inc ::GENOCEA REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.GENOCEA BIOSCIENCES - EXPECTS EXISTING CASH AND CASH EQUIVALENTS ARE SUFFICIENT TO SUPPORT ITS OPERATING EXPENSES & CAPEX REQUIREMENTS INTO H2 OF 2019.GENOCEA BIOSCIENCES INC QTRLY LOSS PER SHARE $0.37.  Full Article

Genocea Biosciences Entered Into Agreement With Oncovir For Manufacture & Supply Of Hiltonol
Wednesday, 31 Jan 2018 05:18pm EST 

Jan 31 (Reuters) - Genocea Biosciences Inc ::GENOCEA BIOSCIENCES SAYS ‍ON JAN 26, CO ENTERED INTO AGREEMENT WITH ONCOVIR FOR MANUFACTURE & SUPPLY OF HILTONOL(REG) (POLY-ICLC)​ - SEC FILING.  Full Article

Bvf Partners Reports A 8.9 Pct Passive Stake In Genocea Biosciences As Of Jan 17
Monday, 29 Jan 2018 06:03pm EST 

Jan 29 (Reuters) - Genocea Biosciences Inc ::BVF PARTNERS L.P. REPORTS A 8.9 PERCENT PASSIVE STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING.  Full Article

Genocea Biosciences, Inc. Announces Pricing Of $55 Mln Concurrent Public Offerings
Wednesday, 17 Jan 2018 08:39am EST 

Jan 17 (Reuters) - Genocea Biosciences Inc ::GENOCEA BIOSCIENCES, INC. ANNOUNCES PRICING OF $55 MILLION CONCURRENT PUBLIC OFFERINGS.GENOCEA BIOSCIENCES INC - PRICES 53.4 MILLION SHARES OF COMMON STOCK & ACCOMPANYING CLASS A WARRANTS TO PURCHASE UP TO 26.7 MILLION SHARES OF COMMON STOCK​.GENOCEA BIOSCIENCES INC - ‍OFFERING AT A COMBINED PRICE TO PUBLIC OF $1.00/SHARE.  Full Article

Genocea Biosciences Announces Proposed Concurrent Public Offerings Of Common Stock
Tuesday, 16 Jan 2018 04:01pm EST 

Jan 16 (Reuters) - Genocea Biosciences Inc ::GENOCEA BIOSCIENCES, INC. ANNOUNCES PROPOSED CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND CLASS A WARRANTS AND SERIES A CONVERTIBLE PREFERRED STOCK AND CLASS A WARRANTS.GENOCEA BIOSCIENCES INC - ‍GENOCEA INTENDS TO USE NET PROCEEDS FROM CONCURRENT OFFERINGS TO SUPPORT ONGOING DEVELOPMENT OF ITS GEN-009 PROGRAM​.  Full Article

Genocea Biosciences inc qtrly ‍loss per share $0.59​
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - Genocea Biosciences Inc :Genocea reports third quarter 2017 financial results.Genocea biosciences - ‍expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018​.Genocea biosciences inc - ‍cash and cash equivalents as of september 30, 2017 were $22.0 million compared to $35.2 million as of june 30, 2017​.Genocea biosciences inc qtrly ‍loss per share $0.59​.Q3 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.  Full Article

Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines
Monday, 25 Sep 2017 04:30pm EDT 

Sept 25 (Reuters) - Genocea Biosciences Inc :Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines.Genocea Biosciences Inc - expects to file an investigational new drug (ind) application by early 2018. For ‍Gen-009.Genocea Biosciences Inc - ‍Genocea is ceasing Gen-003 spending and activities and is reducing its workforce by approximately 40 percent​.Genocea Biosciences Inc - ‍plans to initiate a phase 1 clinical trial for gen-009 in a range of tumor types in first half of 2018​.Genocea Biosciences Inc - ‍expects to report initial immunogenicity data in first half of 2019 for gen-009​.Genocea Biosciences - ‍expects existing cash, cash equivalents sufficient to support operating expenses, capital expenditure requirements to middle of 2018​.Genocea Biosciences Inc - estimates annualized savings of about $6.5 million, , one-time severance and related costs of about $1.1 million in Q3 of 2017.  Full Article

Genocea Biosciences reports qtrly loss per share $‍0.54​
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Genocea Biosciences Inc :Genocea Biosciences reports second quarter 2017 financial results.Genocea Biosciences Inc - Qtrly loss per share $‍0.54​.Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Genocea Biosciences - ‍Expects existing cash, cash equivalents are sufficient to support operating expenses and capital expenditure requirements into 2018​.Genocea Biosciences Inc - ‍Is currently exploring various avenues to secure capital to advance GEN-003 into phase 3 trials​.Genocea Biosciences Inc - ‍Does not intend to commence phase 3 development of GEN-003 until it has secured such capital..  Full Article

BRIEF-Genocea Biosciences Files For Mixed Shelf Of Up To $200 Mln

* GENOCEA BIOSCIENCES INC - FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (https://bit.ly/2GBQyfr) Further company coverage: